Weight gain is a common complication of antipsychotic treatment. Its consequences include
decreased self-esteem, reduced quality of life, reduced adherence with medication and …

Recently proposed criteria for remission by a 'Remission in Schizophrenia Working
Group'have generated considerable interest. We assessed rates, predictors, and correlates …

This article presents a systematic review of pharmacological treatment for negative
symptoms of schizophrenia, based on MEDLINE searches from 1995 to September 2002 to …

Clinicians face a dilemma when choosing between short-acting atypical antipsychotics and
longacting conventional antipsychotics. Atypical antipsychotics offer better safety and …

Background: Observations that antagonists of the N-methyl-d-aspartate (NMDA) receptor of
glutamatergic neurons can mimic symptoms of schizophrenia have raised the hope that …

PURPOSE: Although treatment advances have improved outcomes in schizophrenia,
definitions of remission and recovery are still evolving. Recently proposed criteria for …

The maintained antipsychotic efficacy of risperidone long-acting injectable (RLAI) was
investigated in patients with schizophrenia or other psychoses who were transitioned …

Metabolic syndrome (MetS) has been recognized as a risk factor for cardiovascular
morbidity and mortality in general population and in patients with severe mental illnesses …

Background Whether or not second-generation antipsychotics (SGAs) represent an
advantage over first-generation antipsychotics (FGAs) in the treatment of schizophrenia is …

This study investigated whether illness progression and treatment refractoriness emerge
after relapse in schizophrenia. We compared outcomes in a cohort treated with a …